U.S. stock night market volatility: Fiserv rose 3.55% in the night market
I'm LongbridgeAI, I can summarize articles.Fiserv rose 3.55% in the night session; Soluna rose 16.93% in the night session; AES rose 12.10% in the night session; Sana Biotechnology rose 10.80% in the night session
U.S. Stock Night Market Movements
Fiserv rose 3.55% in the night market. Based on recent important news:
-
On July 8, Mizuho lowered Fiserv's target stock price from $200 to $194 but maintained an "Outperform" rating. This adjustment was based on a downward revision of Clover platform transaction volume expectations; nevertheless, analysts remain confident in its long-term growth.
-
On July 8, MarketBeat pointed out that although Fiserv has a "Moderate Buy" rating, top analysts are more optimistic about five other stocks.
-
On July 7, Marc Chaikin's stock rating system did not list Fiserv as a stock likely to surge in the next three to six months.
Top Gainers in the U.S. Night Market
Soluna rose 16.93% in the night market. Based on recent important news:
-
On July 8, Soluna Holdings announced a 30 MW expansion of its major project Dorothy 2 in Texas and partnered with top Bitcoin mining entities. This expansion solidified its key position in the industry, driving the stock price up 16.93%.
-
On July 8, DeFi Development Corp increased its holdings by 47,272 SOL, worth approximately $7.19 million, demonstrating confidence in the cryptocurrency market, indirectly affecting Soluna's market performance.
-
On July 8, Upexi's holdings of SOL increased by 8.2%. Despite a drop in stock price, its strategy shows continued support for altcoins, influencing related market sentiment.
AES rose 12.10% in the night market. Based on recent important news:
-
On July 8, Bloomberg reported that AES is exploring strategic options, including a potential sale, as several large investment firms have shown acquisition interest, leading to a 12.9% rise in stock price.
-
On July 8, AES's stock price rose 14.3% in after-hours trading due to increased market interest in its potential acquisition.
-
On July 8, AES attracted the attention of infrastructure investors as its stock price has nearly halved over the past two years.
Sana rose 10.80% in the night market. Based on recent important news:
-
On June 23, Sana Biotechnology announced positive six-month follow-up results for its Type 1 diabetes treatment UP421, leading to a 12.1% increase in stock price.
-
On June 29, analysts listed Sana as one of the top ten best healthcare penny stocks, further boosting the stock price.
-
On June 24, JP Morgan reaffirmed Sana's rating, maintaining a target price of $5, enhancing market confidence